Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
² Division of Pulmonary & Critical Care, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Free article

Case Reports

Firas El Chaer et al. Am J Hematol. 2020 Jun.

Free article

. 2020 Jun;95(6):E146-E148.

doi: 10.1002/ajh.25794. Epub 2020 Apr 8.

¹ Division of Hematology and Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
² Division of Pulmonary & Critical Care, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

No abstract available

References

1. Lee DW, Santomasso BD, Locke FL, et al. ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
1. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
1. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404-1419.
1. Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721-729.
1. Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood. 2019;133:2212-2221.